HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)

Yale University159 enrolled

Overview

STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman \& Lawson, Co-PIs) and is being conducted by George Mason University, Yale University, and Howard University.

STRIDE2 will assist in identifying and monitoring individuals' HIV risk behaviors and provide resources to seek treatment for their HIV care and substance use. The goal of STRIDE2 is to examine if there are differences in HIV, drug use, and other outcomes between individuals receiving treatment versus individuals actively using, not actively using and not in treatment, and individuals on Methadone, Suboxone, or in some other treatment.

Study Type

OBSERVATIONAL

Enrollment

159

Conditions

Human Immunodeficiency Virus Acquired Immunodeficiency Syndrome Opiate Addiction Drug Dependence

Interventions

buprenorphineDRUG

To provide buprenorphine for 12 months for those who are interested in receiving it.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. HIV+, confirmed by rapid HIV test 2. Meet DSM-IV criteria for opioid dependence 3. 18 years or older 4. Have health insurance that is accepted at Lab Corp. Exclusion Criteria: 1. Are \<18 years old; 2. Are HIV negative; 3. Are Unable to communicate in English; 4. Are not able to provide informed consent; 5. Do not meet DSM-IV criteria for opioid dependence; 6. Plan to leave the DC area

Locations (1)

Howard University

Washington D.C., District of Columbia, United States

Outcomes

Primary Outcomes

VL <400

Blood test for HIV viral load

Time frame: Month 0

CD4+ cell count

Blood test for HIV CD4+ cell count

Time frame: Month 0

VL <400

Blood test for HIV viral load

Time frame: 6 months

CD4+ cell count

Blood test for HIV CD4+ cell count

Time frame: 6 months

VL <400

Blood test for HIV viral load

Time frame: 12 months

CD4+ cell count

Blood test for HIV CD4+ cell count

Time frame: 12 months

Secondary Outcomes

HIV risk behaviors

Survey for HIV risks

Time frame: Month 0

HIV risk behaviors

Survey for HIV risks

Time frame: 6 months

HIV risk behaviors

Survey for HIV risks

Time frame: 12 months

Retention in HIV care

Survey data for retention

Time frame: Month 0

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.